Legend’s ex vivo design expertise underpins in vivo CAR T efficacy

Legend is the latest company to prove it has figured out how to design and dose in vivo CAR Ts to generate response rates that rival — or beat — the more cumbersome ex vivo cell therapies. Though the question of durability remains unresolved, the modality is living up to all other high expectations in the clinic.

And in a rapidly expanding, emerging field, Legend is applying the learnings it gained through design and development of its best-in-class ex vivo CAR T cell therapy to differentiate from the in vivo competition. Dual targets to sidestep resistance and optimized T cell binding are part of the strategy...